



Lisa Melanson

Partner

Toronto

lmelanson@mccarthy.ca

t. 416-601-7595

Bar Admission

Nova Scotia 1997
New York, USA 2001
Ontario 2005

Law School

Dalhousie University
University of Cambridge

Practices

Intellectual Property

Industries

Life Sciences
Pharmaceutical
Technology
Automotive
Retail & Consumer Markets
Consumer Products

US and International Markets

US Markets

Lisa Melanson is a partner in our Intellectual Property Group in Toronto. Her interdisciplinary practice encompasses the areas of intellectual property and product regulation.

Lisa's intellectual property work focuses on the global acquisition, exploitation, enforcement, and defence of patent and other intellectual property rights. She provides clients with strategic, common-sense advice concerning all phases of patent procurement and protection, from conception to commercialization. She has considerable experience conducting large-scale patentability, infringement, validity, and freedom-to-operate analyses and preparing IP and regulatory landscapes. She also provides IP support on patent litigation matters and IP and regulatory assistance on corporate and commercial transactions, including mergers and acquisitions. She has particular expertise advising pharma clients at the complex interface of drug regulation, patent prosecution, and litigation under the *Patented Medicines (Notice of Compliance) Regulations*.

In her regulatory practice, Lisa advises importers, retailers, manufacturers, and other clients on the regulation of a broad range of products. As a scientist and patent lawyer, Lisa offers a one-stop shop for innovative clients who wish to patent new products and bring them to market. She has considerable experience obtaining patent protection for, and advising on regulatory matters relating to, food and drugs, natural health products, cosmetics, medical devices, electrical equipment, and veterinary products. While cannabis practice is new to many, it is not new to Lisa: she has two decades of experience in the regulation of drugs and controlled substances. She and her team rely on their legal and technical expertise to guide clients through the new cannabis regulatory framework with confidence.

Currently, Lisa is ranked as a Patent Star and named by *Managing IP* as one of the IP STARS' Top 250 Women in IP. She is also listed as a leading lawyer in the area of patents in *Who's Who Legal* and *IAM Patent 1000*.

Lisa received her B.Sc. (Hons.) (Neuroscience / Biology) in 1992 from Dalhousie University, and her LLB in 1995 from Dalhousie Law School. After law school, she served as law clerk to Mr. Justice Wetston of the Federal Court of Canada. In 1998, she obtained her LLM from the University of Cambridge.

Lisa was recognized for practice before the United States Patent and Trademark Office in 2002 and the Canadian Patent Office in 2006. Prior to joining McCarthy Tétrault, she worked as an associate in New York, advising US clients on patent prosecution, litigation, and regulatory matters in the biotechnology, pharmaceutical, and chemical fields. She is licensed in Ontario as a Foreign Legal Consultant with respect to the laws of the State of New York and the United States of America (Federal

Lisa Melanson

Partner

Toronto

lmelanson@mccarthy.ca

t. 416-601-7595

Jurisdiction).

Awards & Rankings

Managing Intellectual Property Magazine: IP Stars - 2019

Patent Star

Intellectual Asset Management (IAM) Patent 1000 - 2019

Recommended in Patents: Transactions and Patents: Prosecution

Managing Intellectual Property Magazine: IP Stars - 2019

Top 250 Women in IP

Managing Intellectual Property Magazine: IP Stars - 2017

Patent Star

Intellectual Asset Management (IAM) Patent 1000 - 2017

Recommended in Patents: Transactions and Patents: Prosecution

Managing Intellectual Property Magazine: IP Stars - 2017

Top 250 Women in IP

Who's Who Legal - 2016

Leading lawyer in the area of patents

Who's Who Legal - 2015

Leading lawyer in the area of patents

Lisa Melanson

Partner

Toronto

lmelanson@mccarthy.ca

t. 416-601-7595

Recent Experience

- **Avara Pharmaceutical Services Inc. acquires major sterile manufacturing facility and development center**
August 31, 2018
- **Nestlé closes perpetual global license deal with Starbucks**
August 28, 2018
- **Thompson Street Capital Partners' portfolio company Tropichem Research Labs, LLC acquires TetraGenx**
March 21, 2018
- **Nestlé acquires Atrium Innovations for US\$2.3B**
March 08, 2018

Recent Insights

- **Modernizing Canada's Industrial Design Regime: Top 10 Changes**
July 03, 2018
- **'Promise Doctrine' Abolished by the Supreme Court of Canada**
June 30, 2017